- Home
- EPSN vs ABOS Comparison
EPSN vs ABOS Comparison
Compare EPSN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSN | ABOS |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EPSN | ABOS |
|---|---|---|
| Price | $4.97 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 111.2K | ★ 139.2K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | ★ 11.33 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,709,605.00 | N/A |
| Revenue This Year | $41.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.51 | ★ N/A |
| Revenue Growth | ★ 46.76 | N/A |
| 52 Week Low | $4.36 | $0.86 |
| 52 Week High | $8.50 | $2.46 |
Technical Indicators
Market Signals| Indicator | EPSN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 54.12 |
| Support Level | $4.77 | $1.85 |
| Resistance Level | $5.11 | $2.02 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 73.08 | 87.00 |
Price Performance
Historical ComparisonAbout EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.